Sign in Subscribe
Cancer research

Teclistamab Shows Promise in Treating Elderly Adults with Relapsed/Refractory Multiple Myeloma

Strategic Insights

— 1 min read

A recent study published in the Blood Cancer Journal suggests that teclistamab, a BCMA-directed bispecific antibody, is safe and efficacious in treating elderly adults with relapsed/refractory multiple myeloma (RRMM). The research, conducted by the University of Texas MD Anderson Cancer Center, analyzed a large cohort of 385 patients, of which 83 (22%) were in the older group (age 75) and 302 (78%) in the younger group. The study found that age was not significantly associated with survival outcomes, and teclistamab was effective in both age groups.

Key Takeaways:

  • The study included 385 patients, with 83 (22%) being 75 years old or older and 302 (78%) being younger.
  • Teclistamab, a BCMA-directed bispecific antibody, was found to be safe and efficacious in treating elderly adults with relapsed/refractory multiple myeloma (RRMM).
  • The study concluded that age was not significantly associated with survival outcomes, suggesting that teclistamab is effective in well-selected patients 75 years old and older.
  • Teclistamab received regulatory approval for RRMM based on the MajesTEC-1 study, which included 24 participants aged 75 or older.
  • The study was funded by the U.S. Department of Health & Human Services | Nih | National Cancer Institute, Leukemia & Lymphoma Society Scholar in Clinical Research Award, and U.S. Department of Health & Human Services | Nih | Nih Clinical Center.
  • The study's findings suggest that teclistamab can be administered to patients 75 years old and older, despite being primarily a cancer of elderly adults.

Statistics:

  • 385 patients were analyzed in the study, with 83 (22%) being in the older group and 302 (78%) in the younger group.
  • 24 participants in the MajesTEC-1 study were aged 75 or older.
  • The study found that age was not significantly associated with survival outcomes.
  • Teclistamab showed promise in treating elderly adults with RRMM, with a high efficacy rate.

Sources:

  • Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer Journal, 2025,15(1):1-6. (Blood Cancer Journal - http://www.nature.com/bcj/index.html).
  • Our news journalists report that more information may be obtained by contacting Oren Pasvolsky, MD Anderson Cancer Center.

Read more